Proposed $60 Million Humaskan Deal Was Not Completed and Ended in September
Key Facts
Davion Healthcare’s proposed acquisition of Humaskan Medical Technology was not completed and ended after the sellers exercised their contractual termination right on September 1, 2026, according to a registration statement amendment filed by Davion with the U.S. Securities and Exchange Commission. The filing said the transaction’s conditions had not been met by the August 31, 2026 deadline. This places the earlier agreement in a different context from the account in the first draft, which described an acquisition of intellectual property alone for $25 million. Davion announced a proposal in June to acquire all of Humaskan, not a completed deal to transfer specific assets. The filing said the transaction was not completed and was no longer pending, meaning the earlier proposal had ended and does not establish the existence of a separate new agreement.
The total consideration proposed for the June transaction was $60 million, split between $10 million in cash and $50 million through the issuance of Davion common shares, according to the company’s statement. The proposal set a reference price of $13 per share to be issued as part of the consideration. The share issuance would also have been subject to a nine-month lock-up period, followed by orderly-disposal arrangements, according to the statement. This meant the largest portion of the proposed consideration was tied to company shares rather than an immediate cash payment. These terms, however, remain part of a deal that was not completed after its conditions were not met by the contractual deadline.
Davion announced on June 22, 2026, that it was adopting a direct-marketing strategy and establishing a distribution platform in the United Kingdom, three days before announcing the proposed Humaskan deal. In its June statement, the company said the joint plan aimed to expand its healthcare technology and intellectual-property portfolio. It also cited expanding product-development and manufacturing capabilities among its stated objectives. The company said these steps could provide additional avenues for revenue growth and commercial expansion. But the strategy statement does not establish that the transaction was completed or that Humaskan’s assets were integrated into Davion’s business.
In its filing with the U.S. Securities and Exchange Commission, Davion said completion of the proposed agreement was conditional on final documentation, regulatory considerations and satisfaction of customary conditions. It later reported in the registration statement amendment that those conditions had not been met by August 31 and that the sellers exercised their termination right the following day. The filing said neither of the two acquisitions addressed in the document had been completed and that they were no longer pending. The company also said its registration of shares with Nasdaq was intended to allow existing shares to trade for registered shareholders. The filing noted that the company would receive no proceeds from the direct listing.